Medtronic’s most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $55.00 short put and a strike $50.00 long put offers a potential 5.26% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $55.00 by expiration. The full premium credit of $0.25 would be kept by the premium seller. The risk of $4.75 would be incurred if the stock dropped below the $50.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.
The RSI indicator is at 71.78 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
United Therapeutics Aims For A Cardiovascular Drug OK
Tue, 22 Oct 2013 19:22:00 GMT
Investor’s Business Daily – United Therapeutics Aims For A Cardiovascular Drug OK
Medtronic of Canada Recognized as One of Canada’s Top 100 Employers for 2014 — for the Fourth Year Running
Tue, 22 Oct 2013 17:16:26 GMT
Marketwired – Medtronic of Canada Ltd. , a trusted Canadian leader in innovative medical technologies and health system solutions, is pleased to have been recognized as one of Canada’s Top 100 Employers for 2014, for …
Medtronic initiates clinical study of recapturable CoreValve Evolut R
Tue, 22 Oct 2013 13:31:52 GMT
theflyonthewall.com – Medtronic announced the first implants in the CoreValve Evolut R Clinical Study, which will evaluate the safety and effectiveness of the new Medtronic CoreValve Evolut R Recapturable System. The primary …
InPlay: Medtronic initiates clinical study of recapturable CoreValve Evolut R
Tue, 22 Oct 2013 13:31:42 GMT
Medtronic Initiates Clinical Study of Recapturable CoreValve Evolut R
Tue, 22 Oct 2013 13:31:01 GMT
Thomson Reuters ONE – First Patients Successfully Treated With Novel `CoreValve Evolut R` Transcatheter Valve MINNEAPOLIS – Oct. 22, 2013 – Medtronic, Inc. (NYSE: MDT) today announced the first implants in the CoreValve Evolut …
Also on Market Tamer…
Follow Us on Facebook